Castle Biosciences’ Founder, President and CEO Derek Maetzold Honored with the CEO of the Year Award by The CEO Magazine
Castle Biosciences (Nasdaq: CSTL) announced that its founder, president and CEO Derek Maetzold has been named CEO of the Year by The CEO Magazine, selected from 586 applicants in their 2025 Executive of the Year Awards program.
Under Maetzold's leadership, Castle has evolved from a startup into a leading diagnostics company with nearly 800 employees. The company has developed proprietary tests for skin cancers, Barrett's esophagus, and uveal melanoma. Castle has also earned recognition as a Top Workplace USA for four consecutive years, reflecting its strong people-first culture and values-driven approach to corporate growth.
Castle Biosciences (Nasdaq: CSTL) ha annunciato che il suo fondatore, presidente e CEO Derek Maetzold è stato nominato CEO dell'Anno da The CEO Magazine, selezionato tra 586 candidati nel programma 2025 Executive of the Year Awards.
Sotto la guida di Maetzold, Castle è passato da startup a una leading diagnostics company con quasi 800 dipendenti. L'azienda ha sviluppato test proprietari per tumori della pelle, esofago di Barrett e melanoma uveale. Castle ha inoltre ottenuto il riconoscimento come Top Workplace USA for four consecutive years, a testimonianza della sua cultura centrata sulle persone e dell'approccio guidato dai valori alla crescita aziendale.
Castle Biosciences (Nasdaq: CSTL) anunció que su fundador, presidente y CEO Derek Maetzold ha sido nombrado CEO del Año por The CEO Magazine, seleccionado entre 586 candidaturas en su programa 2025 Executive of the Year Awards.
Bajo la dirección de Maetzold, Castle ha pasado de ser una startup a convertirse en una empresa diagnóstica líder con cerca de 800 empleados. La empresa ha desarrollado pruebas propietarias para cánceres de piel, esófago de Barrett y melanoma uveal. Castle también ha sido reconocida como Top Workplace USA for four consecutive years, lo que refleja una cultura centrada en las personas y un enfoque de crecimiento corporativo basado en valores.
Castle Biosciences (Nasdaq: CSTL)은 창립자이자 사장 겸 CEO인 Derek Maetzold가 The CEO Magazine에서 올해의 CEO로 선정되었으며, 2025년 Executive of the Year Awards 프로그램에서 586명의 지원자 중에서 뽑혔다고 발표했습니다.
Maetzold의 리더십 아래 Castle은 스타트업에서 선도적 진단 기업으로 성장했고 직원 수 약 800명에 이릅니다. 이 회사는 피부암, 바렛 식도염, 망막유망종에 대한 독자적 테스트를 개발했습니다. Castle은 또한 4년 연속으로 Top Workplace USA로 인정받아 사람을 우선시하는 문화와 가치 중심의 성장 방식이 반영되고 있음을 보여줍니다.
Castle Biosciences (Nasdaq: CSTL) a annoncé que son fondateur, président et PDG Derek Maetzold a été nommé CEO de l'Année par The CEO Magazine, sélectionné parmi 586 candidatures dans leur programme Executive of the Year Awards 2025.
Sous la direction de Maetzold, Castle est passé d'une start-up à une entreprise diagnostique de premier plan avec environ 800 employés. L'entreprise a développé des tests propriétaires pour les cancers de la peau, l'œsophage de Barrett et le mélanome uvéal. Castle a également été reconnue comme Top Workplace USA for four consecutive years, reflétant une culture axée sur les personnes et une approche de croissance guidée par les valeurs.
Castle Biosciences (Nasdaq: CSTL) gab bekannt, dass Gründer, Präsident und CEO Derek Maetzold zum CEO des Jahres von The CEO Magazine ernannt wurde, ausgewählt aus 586 Bewerbern im Programm Executive of the Year Awards 2025.
Unter Maetzolds Führung hat sich Castle von einem Startup zu einem führenden Diagnostikunternehmen mit fast 800 Mitarbeitern entwickelt. Das Unternehmen hat proprietäre Tests für Hautkrebs, Barrett-Ösophagus und Uvealmelanom entwickelt. Castle hat außerdem Anerkennung als Top Workplace USA for four consecutive years erhalten, was seine mitarbeiterorientierte Kultur und den werteorientierten Wachstumsansatz widerspiegelt.
Castle Biosciences (Nasdaq: CSTL) أعلنت أن مؤسسها ورئيسها ومسيرها التنفيذي Derek Maetzold قد فُضِل كـ CEO of the Year من قبل The CEO Magazine، مختار من بين 586 مقدمًا في برنامج جوائز Executive of the Year لعام 2025.
تحت قيادة Maetzold، تطورت Castle من شركة ناشئة إلى شركة تشخيصية رائدة مع قرابة 800 موظف. طورت الشركة اختبارات حصرية لأورام الجلد، ومريء باريت، ومالانوما عُقِدَة العين. كما حصدت Castle أيضًا تقديرًا كأفضل مكان عمل في الولايات المتحدة Top Workplace USA for four consecutive years، مما يعكس ثقافة تضع الناس أولاً ونهج النمو القائم على القيم.
Castle Biosciences（Nasdaq: CSTL）宣布，其创始人、总裁兼首席执行官 Derek Maetzold 已被 CEO of the Year 评为年度首席执行官，来自 The CEO Magazine，在 2025 年的 Executive of the Year Awards 项目中从 586 名申请人中脱颖而出。
在 Maetzold 的领导下，Castle 已从初创阶段发展为领先的诊断公司，拥有近 800 名员工。公司开发了用于皮肤癌、Barrett 食管和脉络膜黑色素瘤的专有检测方法。Castle 还因连续四年被评为 Top Workplace USA，凸显其以人为本的企业文化和以价值观驱动的增长方式。
- None.
- None.
Maetzold recognized among 586 applicants to The CEO Magazine’s 2025 Executive of the Year Awards — United States program
FRIENDSWOOD, Texas, Oct. 01, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that its founder, president and chief executive officer Derek Maetzold has been awarded the CEO of the Year by The CEO Magazine. The Executive of the Year Awards program recognizes senior executives driving measurable impact, innovation and inspiration.
“This honor affirms what we at Castle have long known: Derek is a visionary leader whose ability to pair scientific innovation with a people-first approach has made a marked impact on patient care and our company,” said Frank Stokes, chief financial officer of Castle Biosciences. “His leadership has grown Castle from a startup into a leading diagnostics company, while fostering a culture that inspires and empowers nearly 800 employees. His unwavering commitment to improving patient outcomes and advancing the standard of care make him truly deserving of this recognition as CEO of the Year.”
Under Maetzold’s leadership, Castle has become a recognized innovator in the diagnostics field, with a portfolio of proprietary tests addressing critical challenges in skin cancers, Barrett’s esophagus and uveal melanoma. Beyond scientific and commercial success, Maetzold and the leadership team have cultivated a people-first culture, earning Castle four consecutive years of recognition as a Top Workplace USA, driven solely by employee feedback. His commitment to patients, innovation and culture has positioned Castle as both a leader in personalized medicine and a role model for values-driven corporate growth.
Earlier this year, Maetzold was named one of just 10 finalists selected from a pool of 586 applicants to the Executive of the Year Awards program. On Oct. 1, 2025, The CEO Magazine announced Maetzold as its CEO of the Year.
About Castle Biosciences
Castle Biosciences (Nasdaq: CSTL) is a leading diagnostics company improving health through innovative tests that guide patient care. The Company aims to transform disease management by keeping people first: patients, clinicians, employees and investors.
Castle’s current portfolio consists of tests for skin cancers, Barrett’s esophagus and uveal melanoma. Additionally, the Company has active research and development programs for tests in these and other diseases with high clinical need, including its test in development to help guide systemic therapy selection for patients with moderate-to-severe atopic dermatitis seeking biologic treatment. To learn more, please visit www.CastleBiosciences.com and connect with us on LinkedIn, Facebook, X and Instagram.
DecisionDx-Melanoma, DecisionDx-CMSeq, i31-SLNB, i31-ROR, DecisionDx-SCC, MyPath Melanoma, TissueCypher, DecisionDx-UM, DecisionDx-PRAME and DecisionDx-UMSeq are trademarks of Castle Biosciences, Inc.
About the Executive of the Year Awards
The CEO Magazine’s Executive of the Year Awards is a prestigious program recognizing outstanding senior executives who drive success and make a meaningful impact across industries. Now in its second year in the United States, the awards celebrate leadership excellence with winners announced online.
Investor Contact:
Camilla Zuckero
czuckero@castlebiosciences.com
Media Contact:
Allison Marshall
amarshall@castlebiosciences.com
Source: Castle Biosciences Inc.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/06ba54e7-69f3-410b-a863-2ff1b4e6da4e
FAQ
Who is Derek Maetzold and what award did he receive in 2025?
How many employees does Castle Biosciences (CSTL) currently have?
What types of diagnostic tests does Castle Biosciences (CSTL) develop?
What workplace recognition has Castle Biosciences (CSTL) received?
How many applicants were considered for The CEO Magazine's 2025 Executive of the Year Awards?
